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Abstract Hepatic encephalopathy (HE) is a common and
severe neuropsychiatric complication present in acute and
chronic liver disease. The unique advantages of high field
1H MRS provide a method for assessing pathogenic mech-
anism, diagnosis and monitoring of HE, as well as for
treatment assessment or recovery after liver transplantation,
in a reproducible and reliable non-invasive way. The pur-
pose of the present review is to present some new features of
in vivo proton Magnetic Resonance Spectroscopy (1H
MRS) at high magnetic fields combined with some basic
requirements for reliable metabolic profiling. Finally, in
vivo applications of 1H MRS in different HE animal models
are presented.
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Introduction
Hepatic encephalopathy (HE) is a common and severe neu-
ropsychiatric complication present in acute and chronic liver
disease (i.e. 30 to 50 % of patients with cirrhosis exhibit HE
(Munoz 2008)), which is characterized by an array of cog-
nitive and fine motor deficits progressively leading to al-
tered mental status, coma and death (Norenberg et al. 2009;
Caudle et al. 2010; Butterworth 2003). Minimal HE (mHE)
occurs in approximately 70 % of the patients with chronic
liver disease (CLD) and is defined by the presence of
cognitive impairment on psychometric testing in absence
of any overt clinical signs (McPhail and Taylor-Robinson
2010). The diagnosis of HE is traditionally done using
neuropsychological tests together with the assessment of
liver function, but it lacks consensus and has never been
standardized especially in mHE (Rovira et al. 2008;
McPhail and Taylor-Robinson 2010). Consequently, there
is an urgent need for new unified tools for reliable diagnostic
in HE.
Although, the molecular basis for the neurological disor-
der in HE remains elusive, increasing evidence points to
ammonia as a key factor (Braissant et al. 2012; Cagnon and
Braissant 2007; Felipo and Butterworth 2002; Norenberg et
al. 2009; Butterworth 2003; Cooper and Plum 1987).
Ammonia is mainly produced in the gut by intestinal
urease-positive bacteria and amino acid metabolism, and
under normal circumstances undergoes a high degree of
extraction by the urea cycle in the liver. In addition to the
gut sources, it was reported the ammonia can be liberated
by kidney or muscle during and after vigorous exercise
(Cooper and Plum 1987). In the diseased liver ammonia
passes into the blood circulation and thereby enters the
brain through the blood–brain barrier, where its main toxic
effects occur. Cerebral ammonia removal relies on formation
of glutamine by glutamine synthetase (GS) in astrocytes. It is
hypothesized that the unique astrocytic expression of GS
(Norenberg 1979) underlies the relative sensitivity of astro-
cytes to ammonia, leading to astrocytes swelling and finally to
brain edema.
The precise mechanisms and their relative contributions
leading to astrocytes swelling and consequently to brain
edema are very complex and not fully elucidated, but recent
studies showed that the main pathogenic mechanisms
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involved in HE are the following: amino acids disturbances;
alterations in neurotransmission; cerebral energy distur-
bance; alteration of nitric oxide synthesis and oxidative
stress which leads to induction of the mitochondrial perme-
ability transition; impairment of axonal and dendritic growth
during brain development; signaling transduction pathways;
alterations in channels and transporters activity (Braissant et
al. 2012; Cagnon and Braissant 2007; Butterworth 2003;
Felipo and Butterworth 2002; Norenberg et al. 2009; Leke et
al. 2011; Cooper and Plum 1987; Brusilow and Traystman
1986; Brusilow et al. 2010). In this context, several hypoth-
eses have been proposed, suggesting that a byproduct of
ammonia metabolism rather than ammonia per se could be
the main cause of ammonia toxicity to the brain. Approxi-
mately 25 years ago the osmotic gliopathy theory (gluta-
mine hypothesis) was elaborated, postulating that glutamine
can act as an osmolyte and that its increase leads to a shift of
water into astrocytes (Brusilow and Traystman 1986). Recent-
ly, another hypothesis was proposed, the “Trojan horse”, where
glutamine acts as a carrier of ammonia across the mitochon-
drial membrane. Once in the mitochondria, glutamine is hy-
drolyzed by phosphate-activated glutaminase to glutamate and
ammonia, which further gives rise to excessive production of
free radicals inducing opening of the mitochondrial permeabil-
ity transition (Albrecht and Norenberg 2006). More details
about the hypotheses, related evidences and controversies can
be found in (Brusilow et al. 2010; Desjardins et al. 2012; Rama
Rao et al. 2012).
Although there is extensive research examining the bio-
chemistry of ammonia-induced glutamine accumulation and
energy failure in cultured astrocytes and neurons, in vivo
data are often missing. The importance of in vivo data
cannot be understated when it comes to astrocyte and neu-
ronal metabolism, as both cell types are exquisitely sensitive
to certain drugs, and certainly to ischemia. Understanding
the pathogenic mechanisms involved in HE, finding the
reliable markers which would assess in a reproducible way
the different degrees of HE or unraveling new therapeutic
targets to protect the brain form ammonia toxicity, requires
experimental models focusing on the brain in its cellular
complexity, with neurons and glial cells interacting together
(in vivo rodent models, ex-vivo CNS organotypic cultures,
in vitro primary 3D brain cell cultures in aggregates).
In the last decades, Magnetic Resonance Imaging (MRI)
and Magnetic Resonance Spectroscopy (MRS) became
powerful and reliable diagnostic tools with unique advan-
tages: they are applicable in vivo, non-invasively and con-
sequently longitudinally, thus allowing to monitor disease
progression and/or effect of treatment, and made a bridge
between the clinical diagnostics and basic research. There-
fore, MRI combined with MRS might provide a method for
assessing pathogenic mechanisms, diagnosis and monitor-
ing of HE, as well as for treatment assessment or recovery
after liver transplantation in a reproducible and reliable non-
invasive way.
The present review will focus on presenting some new
features of in vivo proton Magnetic Resonance Spectrosco-
py (1H MRS) at high magnetic fields combined with some
basic requirements for reliable metabolic profiling. Finally,
in vivo applications of 1HMRS in different HE animal models
will be presented.
In vivo Proton Magnetic Resonance Spectroscopy at high
fields
Proton Magnetic Resonance Spectroscopy (1H MRS) has
proven to be a powerful tool to non-invasively investigate in
vivo brain metabolism of animals and humans in different
neurological disorders (Williams 1999). Some studies
reported the in vivo investigation and monitoring of HE
using 1H MRS in humans and animal models (Cauli et al.
2011; Cauli et al. 2007; Cudalbu et al. 2012b; Cudalbu et al.
2010; Fitzpatrick et al. 1989; Nyberg et al. 1998; Shen et al.
1998; Braissant et al. 2012; Haussinger et al. 2000; Rovira
et al. 2008; Spahr et al. 2002; Williams 1999; Bates et al.
1989; McPhail and Taylor-Robinson 2010; Butterworth
2003; Kreis et al. 1991; Kreis et al. 1992; Ross et al.
1994). The main finding of these studies was the increase
in brain glutamine concentration.
In humans, previously published studies were performed
at magnetic fields of 1.5 T and only few at 3 T, using echo
times (TE) ≥20 ms and leading to the quantification of only
few metabolites (i.e. sum of glutamine and glutamate, total
creatine, total choline and myo-inositol) (Rovira et al. 2008;
Haussinger et al. 2000; Spahr et al. 2002; Cordoba et al.
2002; Cordoba et al. 2001; Williams 1999; Butterworth
2003; Kreis et al. 1991; Kreis et al. 1992; Ross et al.
1994). As shown by these studies, several pathogenic mech-
anisms involved in HE can be explored in vivo using 1H
MRS, e.g. amino acid disturbances (e.g. modifications in the
concentrations of glutamine, glutamate), osmoregulation
(e.g. decrease of myo-inositol, total choline concentrations),
cerebral energy disturbance (e.g. increase in lactate concen-
tration). However, at magnetic fields of 1.5 T the separation
of glutamine and glutamate is not possible, while at 3 T is
difficult, therefore only the sum of these two metabolites
(named as Glx) was reported. Additionally, at longer echo
times (TE above 20 ms), the number of spectral lines, which
can be used for quantification, is reduced. This is due to
phase distortion of multiplets produced by coupled spin
systems and to fast transversal relaxation (T2 relaxation)
leading to signal reduction, which prevents observation of
small peaks in the spectrum. Moreover, correction factors
for the T2 relaxation times when performing absolute quan-
tification are required.
168 Metab Brain Dis (2013) 28:167–174
In this context, the detection of additional brain metabolites
is required to accurately assess the pathogenic mechanisms and
for monitoring/diagnostic in HE. The high magnetic field
strengths (≥7 T) combined with the possibility of acquiring
spectra at very short echo time (<10 ms) have increased the
number of in vivo detectable brain metabolites to about 20
metabolites in animal models and humans. This so-called
neurochemical profile at high magnetic fields comprises: glu-
cose (Glc), lactate (Lac), creatine (Cr), phosphocreatine (PCr),
alanine (Ala) (markers of energy metabolism); phosphocholine
(PCho), glycerophosphocholine (GPC), phosphoethanolamine
(PE), N-acetylaspartate (NAA), N-acetylaspartylglutamate
(NAAG) (markers of myelination/cell proliferation); glutamate
(Glu), glutamine (Gln), aspartate (Asp), γ-aminobutyrate
(GABA), glycine (Gly) (markers of neurotransmitter metabo-
lism); taurine (Tau), myo-inositol (Ins) (markers of osmoregu-
lation) and ascorbate (Asc), glutathione (GSH) (antioxidants)
(Fig. 1b and c).
Overall, increased intrinsic signal-to-noise ratio (in-
creased sensitivity), chemical shift dispersion (increased
spectral resolution) and decreased strong coupling effects
are the main benefits of high magnetic fields, which are
expected to be useful for low concentration metabolites,
strongly overlapped metabolites and for metabolites having
complex multiplet patterns, leading to an improved quanti-
fication precision and accuracy (Mekle et al. 2009; Mlynarik
et al. 2008a; Tkac et al. 2009). Moreover, acquisitions
performed at a short echo time enable to obtain high quality
spectra with resolved lines of many metabolites due to
minimal phase distortions of multiplets of coupled spin
systems such as Glu, Gln, Ins, Glc, Asp, Ala, GABA, Asc,
PE, Gly and Tau (Mekle et al. 2009; Mlynarik et al. 2008a;
Tkac et al. 2009), thus increasing the amount of biochemical
information. Signal loss due to T2 relaxation is reduced and
consequently a more precise quantification is expected.
Acquisitions at short TE and long repetition times (TR)
(fully relaxed spectra) are considered to be a good choice
for absolute quantification, since the effects of relaxation are
minimized. Macromolecule contributions at short echo
times need also to be considered. Several techniques have
been used to overcome this issue and were presented more
in details elsewhere (Cudalbu et al. 2012c).
These advantages of high magnetic field spectroscopy are
also accompanied by some factors that can decrease the
spectral quality and consequently the quantification preci-
sion. A main factor is related to the increased peak line-
widths (in Hz) since magnetic field inhomogeneities
increase with the magnetic field due to the fact that magnetic
susceptibility differences between tissues, blood, bone and
air (in Hz) are proportional to the static magnetic field (B0).
Resonance frequency of nuclear spins is proportional to a
magnitude of the B0. When B0 is spatially inhomogeneous,
resonance frequency of 1H nuclei is not the same over the
measured volume of a tissue, resulting in broadening spec-
tral lines and in decreasing spectral resolution and signal-to-
noise ratio. An adjustment of the B0 inhomogeneity for
1H
MRS is technically rather challenging in rodent brain due to
the small size of the brain, and powerful first- and second-
order B0 corrections (shims) are necessary (Tkac and Gruetter
2005). A second factor is the chemical shift displacement error
which is related to frequency selective localization. The use of
stronger magnetic fields gradients can limit this artefact; how-
ever, attention has to be paid to eddy current effects on the B0
stability. T1 relaxation times have been shown to increase with
Fig. 1 a In vivo T2 weighted
image acquired in the rat brain at
9.4 T showing the localization of
the volume of interest in the
hippocampus; b In vivo 1HMRS
spectrum acquired using the
SPECIAL sequence in the
hippocampus of the rat brain at
9.4 T (TE02.8 ms, TR04 s, 160
averages, 10 min of acquisition).
Note the high spectral resolution
obtained with efficient B0
shimming, the efficient water
suppression, the localization
performances and the flat
baseline, c LCModel
quantification result, from
bottom to top: the raw in vivo
spectrum (in black), the
LCModel fit (in red) and the
quantification residual
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magnetic field (de Graaf et al. 2006) leading to increased
signal saturation for shorter repetition times (TR). This can
be overcome by increasing TR, which in turn would increase
the total acquisition time or decrease signal-to-noise in the
same total acquisition time. However, no further increase in T1
relaxation times has been observed beyond 9.4 T (Cudalbu et
al. 2009).
The main goal of localized in vivo 1H MRS is the reliable
quantification of the concentration of as many metabolites
as possible in a well-defined region of the brain. Metabolite
concentration ratios are often used as markers of changes in
brain metabolite concentrations. However, for an accurate
interpretation of these changes in different neurological dis-
eases, absolute metabolite concentrations can be more valu-
able. Accurate and precise quantification of brain metabolites,
independently of the magnetic field, is challenging and
depends on: 1) spectral quality (signal–to-noise ratio, spectral
resolution, water suppression, localization performances,
baseline, chemical shift displacement error and eddy current
correction), 2) reliable data processing (estimate of the signal
amplitude or peak area); 3) quantification strategies (conver-
sion into concentration units). Overall, the main features of a
good quality spectrum acquired in the hippocampus of the rat
brain are shown in Fig. 1b. The signal-to–noise ratio depends
on: the efficiency of B0 shimming, the performances of radio-
frequency coils and localization sequences, the B0 field
strength, the precise adjustment of rephasing gradients in
localization sequences and subject motion. Poor water sup-
pression can lead to the presence of residual water signal in the
acquired spectrum and consequently affects the spectral base-
line (a flat baseline is critical for reliable quantification).
Localization performance of the acquisition sequence repre-
sents the ability to provide a maximum signal from a selected
volume with minimum contamination from outside. The sub-
cutaneous lipids represent the main source of contamination in
the region 0.5–2 ppm and their presence, typically as phase
distorted signals, could lead to an overestimation of the metab-
olites present in this spectral region (e.g. lactate, alanine,
GABA). The use of outer volume suppression bands (OVS)
can limit this contamination (Mlynarik et al. 2008a; Tkac and
Gruetter 2005). Any misadjustment of the parameters in the
pulse sequence can affect the spectral quality leading to unre-
liable metabolite concentrations.
The choice of the data processing method is also impor-
tant, since many algorithms depend on user input which
leads to additional inaccuracies. Metabolite concentrations
are usually determined by fitting the measured in vivo 1H
MRS spectrum to a linear combination of spectra of indi-
vidual metabolites (the metabolite basis set), making feasi-
ble the quantification especially for low concentration
metabolites (Cudalbu et al. 2012c; Mlynarik et al. 2008a;
Tkac et al. 2009) (Fig. 1c). The metabolite basis set can be
obtained by measuring aqueous solutions of pure metabolites
(under the identical conditions as the in vivo spectra) or by
quantummechanics simulations, based on the density-matrix
formalism, using published values of spin-spin coupling
constants and chemical shifts, and the relevant acquisition
parameters (Cudalbu et al. 2008; Cudalbu et al. 2012c).
Well-known time and frequency–domain algorithms, based
on metabolite basis sets, are currently used for accurate
quantification (i.e. QUEST from jMRUI software working
in the time domain, LCModel working in the frequency
domain, AQSES working in time domain and TDFD work-
ing in both time and frequency domains) (Fig. 1c).
While 1H MRS (also called single voxel spectroscopy)
allows signal detection from a well-defined single volume,
usually positioned in a specific brain region, proton spec-
troscopic imaging (1H MRSI), also called chemical shift
imaging (CSI), allows the simultaneous detection of multi-
ple spectra from different brain regions and thus the spatial
distribution of metabolites in various regions of the brain
can be efficiently studied. Spectroscopic imaging can be per-
formed in rodents with μL spatial resolution, which is com-
parable in resolution to animal positron emission tomography
(PET) (Mlynarik et al. 2008b).
1H MRS in models of hyperammonemia
Since ammonia is believed to be the main culprit in HE,
several animal models of hyperammonemia (HA) were used
to study the effect of ammonia per se without liver failure (e.g.
single i.p. injection of ammonia or continuous infusion for
several hours). Very few studies have used in vivo 1H MRS
and 1H MRSI to investigate brain metabolism in animal
models of HA without liver failure (Cudalbu et al. 2012b;
Cauli et al. 2007; Fitzpatrick et al. 1989; Cudalbu et al. 2010).
There are two ways in which the brain can metabolize ammo-
nia: the reductive amination of α-ketoglutarate to glutamate
via the glutamate dehydrogenase reaction (GDH) and the
synthesis of glutamine from glutamate and ammonia by glu-
tamine synthetase reaction (GS), the last being the major
metabolic pathway for ammonia detoxification (Brusilow et
al. 2010; Cooper 2011, 2012).
Our group recently studied the brain metabolism in ani-
mal models of HA without liver failure using in vivo 1H
MRS and 1H MRSI (Cudalbu et al. 2012b; Cudalbu et al.
2010). Using 1H MRS at high magnetic field (9.4 T) we
showed that the Gln concentration increased immediately
after the starting of ammonium infusion and continued to
increase linearly over time (2.3±0.4 μmol/g before the
infusion which increased to 17.7±4.0 μmol/g at the end of
the infusion) without significant changes in the concentra-
tion of other brain metabolites (Fig. 2a). The linear and
continuous increase of total Gln during the period of am-
monium chloride infusion observed in our in vivo 1H MRS
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data implies increased anaplerosis (Berl et al. 1962; Shen et
al. 1998; Zwingmann 2007), which appears to be coupled to
the ammonia detoxification pathway. From the linear fit of
the time courses of total Gln we obtained a net Gln accu-
mulation of 0.033±0.001 μmol/g/min, suggesting no delay
in Gln accumulation and consequently in anaplerosis. We
further continued our studies on HA by mapping brain
metabolism in different brain regions in the same rat model
using 1H MRSI (Cudalbu et al. 2010). Figure 2b illustrates
the metabolic maps of Gln, superimposed on the anatomical
T2w images and acquired at different time points during
ammonium chloride infusion. As for the data obtained using
1H MRS, the increase in the Gln pool at different time points
during infusion was apparent from the maps with no sub-
stantial differences for the other brain metabolites. Even
though before infusion, the Gln map did not show any
substantial differences among brain regions, during infusion
the Gln increase showed a specific brain region pattern,
i.e. higher in cortex than in hippocampus (at 5.5 h of
NH4
+infusion: 16.2±2.7 μmol/g in the cortex and 11.5±
1.2 μmol/g in the hippocampus, p00.03) (Fig. 2b).
Consequently, these results showed a higher net gluta-
mine synthesis flux in cortex than in hippocampus. In a
similar way, Cauli et al (2007) performed single voxel 1H
MRS in cerebellum and substrantia nigra after i.p. injection of
ammonium acetate. Surprisingly, they did not report the Gln
concentrations, however they showed a decrease of NAA in
cerebellum and an increase of Ins in both investigated brain
regions, which were prevented by blocking the NMDA recep-
tors. The decrease of NAA was reported to reflect neuronal
damage, whereas Ins increase was suggestive of the presence
of vasogenic edema. Moreover, the authors in (Fitzpatrick et
al. 1989) showed a decrease in Glu concentrations and an
increase in Lac concentrations additionally to Gln increase
during ammonium acetate infusion using single voxel 1H
MRS. The authors suggested that the increase of Lac was
more likely a result of a mismatch between the rate of glycol-
ysis and the activity of tricarboxylic acid cycle (TCA), rather
than an attempt by the brain to buffer incoming ammonia.
1H MRS in models of acute liver failure
In vivo 1HMRS has also been used to study brain metabolism
in few experimental models of acute liver failure (ALF) (e.g.
galactosamine or carbon tetrachloride administration, porto-
caval anastomosis followed by hepatic artery ligation, etc.)
(Nyberg et al. 1998; Chavarria et al. 2010; Cauli et al. 2011;
Bates et al. 1989; Bosman et al. 1990). As for HA models,
these studies reported an increase of brain Gln concentration
in ALF. In addition, these studies reported alterations in brain
lactate concentration at later stages of the disease and the
presence of brain edema. The authors reported that these
changes in brain metabolism were probably caused by the
exposure of the brain to ammonia (Chavarria et al. 2010). The
mechanisms leading to an increase of Lac are not clear,
Fig. 2 a In vivo brain 1H MRS spectra acquired in a rat model of HA at
9.4 T. From top to bottom spectrum acquired before ammonium infusion
and spectrum acquired after 9 h of infusion; b In vivo metabolic maps of
glutamine acquired in a rat brain during ammonium infusion, superim-
posed on the anatomical T2 weighted images and acquired at different time
points before and during infusion; c In vivo metabolic maps of glutamine
acquired in a rat brain before and 5 weeks after BDL, and superimposed on
the anatomical T2 weighted images; d In vivo brain
1H MRS spectra
acquired in a rat model of CLD at 9.4 T. From top to bottom spectrum
acquired before BDL and spectrum acquired 8 weeks after BDL
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however this increase might be an indicator of brain energy
impairment secondary to ammonia-induced brain edema
(Chavarria et al. 2010). In the same context, it was shown
ex-vivo (brain extracts) that lactate and alanine synthesis was
increased in ALF using high resolution 1H/13C nuclear mag-
netic resonance spectroscopy (Chatauret et al. 2003). This
study suggested that a disturbance in brain glucose metabo-
lism rather than Gln accumulation might be the major cause of
cerebral complications in ALF.
1H MRS in models of chronic liver disease
While few studies using biochemical methods have been
performed ex-vivo (brain extracts) or on cultured cells
(astrocytes or neurons), no in vivo longitudinal 1H MRS
studies were performed, to our knowledge, in experimental
animal models of chronic liver disease (CLD) to assess the
kinetics of glutamine, brain osmolyte changes and/or brain
edema in combination with brain energy metabolism using
1H MRS. These previous ex-vivo studies reported increased
cerebral glutamine and ammonia levels with sometimes
reductions in brain osmolytes reflecting disturbances in
cell-volume homeostasis. It has been suggested that the
differences in brain osmolytes could partially explain the
differences in frequency of brain edema between acute and
chronic liver failure (Cordoba et al. 1998; 1996; Cordoba
1996). In a recent study, our group characterized for the first
time the in vivo and longitudinal progression of HE in a rat
model of CLD using 1H MRS, 1H MRSI (Fig. 2c and d) and
Diffusion Tensor Imaging (DTI) (Cudalbu et al. 2012a). We
imaged the in vivo spatial distribution of 12 metabolites (i.e.
Gln, Glu, Cr, PCr, tCho, Ins, Tau, Lac, NAA + NAAG, PE,
Glc, GABA) in various brain structures (cortex, hippocam-
pus and thalamus) before and weekly (for 8 weeks) after
CLD induced by bile duct ligation (BDL). Our preliminary
data showed that Gln was increased at all time points after
BDL reaching ~300 % at 8 weeks. Among the other brain
osmolytes only Ins and tCho decreased significantly over time
(~10 % in the first week, reached ~30 % and even~80 % for
tCho 8 weeks after BDL), whereas Tau showed a smaller
(~10–20 %) but significant decrease. The sum of the main
brain osmolytes (Gln, Ins, tCho, Tau, Cr) was constant over
time, presumably to compensate for the Gln increase. It is
interesting to note the cellular localization of these brain
osmolytes: Ins was reported to be highly concentrated in glial
cells (Brand et al. 1993) and Tau to be present in both neurons
and astrocytes (Urenjak et al. 1993). The osmotic imbalance
created by the continuous increase of Gln is likely to be
compensated by a concomitant decrease of other idiogenic
osmolytes resulting in minimal brain edema (as suggested by
the DTI measurements), prior to the appearance of severe
neurological signs in CLD.
Finally, it has to be emphasized that the differences in the
neurochemical profile betweenHA and CLD are clearly visible
when comparing Fig. 2a and d. Even thoughGln was increased
in both cases, the decrease in the brain osmolytes was present
only in CLD. Additionally, in CLD glutamine increased sim-
ilarly in all brain regions, contrary to HAwhere we measured a
higher increase of Gln in the cortex (Fig. 2b and c).
Conclusion and future perspectives
As can be seen from the present review, 1H MRS has proven
to be a very useful tool for assessing several pathological
mechanisms involved in HE and also for performing an
overall diagnostic in HE using the increase of brain gluta-
mine as a bio-marker and the concomitant decrease of other
brain osmolytes (e. Ins, tCho) in CLD. The non-invasive
applicability of this technique combined with the unique
advantages of high magnetic fields allows, as shown here,
a longitudinal assessment of brain glutamine concentrations
during disease progression (in humans and animal models),
as well as of energy metabolism (Glc, Ala, Lac, Cr, PCr),
osmoregulation, neurotransmitter metabolism (Asp, GABA,
Gly, Glu) and oxidative stress (Asc, GSH). The extraordi-
nary developments in 1H MRS combined with other in vivo
MR imaging/spectroscopy techniques (DTI, 13C MRS, 31P
MRS, etc.) promises new perspectives for a better under-
standing of pathogenic mechanisms involved in HE but also
for a more reliable diagnostic in HE by establishing precise
correlations between different profiles of metabolites and the
degrees of HE.
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